Rare diseases
Investigational molecules
Locations
300 Park Avenue, 10022-7402, United States
Seelos Therapeutics Inc. focuses on clinical research in spinocerebellar ataxia type-3 (SCA3), a progressive neurodegenerative disorder affecting motor coordination and neurological function.
The sponsor’s trial activity is centered on therapeutic evaluation for adults living with SCA3, with research sites distributed across multiple countries.
Seelos Therapeutics Inc. runs clinical trials in conditions such as Hereditary ataxia, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
